134 related articles for article (PubMed ID: 31332244)
1. Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.
Pieters T; T'Sas S; Demoen L; Almeida A; Haenebalcke L; Matthijssens F; Lemeire K; D'Hont J; Van Rockeghem F; Hochepied T; Lintermans B; Reunes L; Lammens T; Berx G; Haigh JJ; Goossens S; Van Vlierberghe P
Sci Rep; 2019 Jul; 9(1):10577. PubMed ID: 31332244
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia.
Liu T; Jankovic D; Brault L; Ehret S; Baty F; Stavropoulou V; Rossi V; Biondi A; Schwaller J
Leukemia; 2010 Mar; 24(3):601-12. PubMed ID: 20072157
[TBL] [Abstract][Full Text] [Related]
3. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo.
Andreasson P; Schwaller J; Anastasiadou E; Aster J; Gilliland DG
Cancer Genet Cytogenet; 2001 Oct; 130(2):93-104. PubMed ID: 11675129
[TBL] [Abstract][Full Text] [Related]
4. The Runx genes: lineage-specific oncogenes and tumor suppressors.
Cameron ER; Neil JC
Oncogene; 2004 May; 23(24):4308-14. PubMed ID: 15156187
[TBL] [Abstract][Full Text] [Related]
5. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
6. The Runx genes as dominant oncogenes.
Cameron ER; Blyth K; Hanlon L; Kilbey A; Mackay N; Stewart M; Terry A; Vaillant F; Wotton S; Neil JC
Blood Cells Mol Dis; 2003; 30(2):194-200. PubMed ID: 12732183
[TBL] [Abstract][Full Text] [Related]
7. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
8. A novel retrovirus provides the cooperating oncogenic event(s) required to demonstrate the tumor suppressor activity of p15Ink4b in myeloid cells in vivo.
Wolff L; Garin MT; Koller R; Bies J; Tessarollo L; Anver MR; Powell D; Perella C
Blood Cells Mol Dis; 2004; 32(1):226-31. PubMed ID: 14757439
[TBL] [Abstract][Full Text] [Related]
9. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.
Blyth K; Terry A; Mackay N; Vaillant F; Bell M; Cameron ER; Neil JC; Stewart M
Oncogene; 2001 Jan; 20(3):295-302. PubMed ID: 11313958
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.
Rawat VP; Cusan M; Deshpande A; Hiddemann W; Quintanilla-Martinez L; Humphries RK; Bohlander SK; Feuring-Buske M; Buske C
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):817-22. PubMed ID: 14718672
[TBL] [Abstract][Full Text] [Related]
11. MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice.
Carella C; Bonten J; Rehg J; Grosveld GC
Leukemia; 2006 Sep; 20(9):1582-92. PubMed ID: 16810199
[TBL] [Abstract][Full Text] [Related]
12. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.
Rivera-Munoz P; Laurent AP; Siret A; Lopez CK; Ignacimouttou C; Cornejo MG; Bawa O; Rameau P; Bernard OA; Dessen P; Gilliland GD; Mercher T; Malinge S
Blood Adv; 2018 Jul; 2(13):1616-1627. PubMed ID: 29986854
[TBL] [Abstract][Full Text] [Related]
13. Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene.
Lai CK; Moon Y; Kuchenbauer F; Starzcynowski DT; Argiropoulos B; Yung E; Beer P; Schwarzer A; Sharma A; Park G; Leung M; Lin G; Vollett S; Fung S; Eaves CJ; Karsan A; Weng AP; Humphries RK; Heuser M
PLoS One; 2014; 9(11):e112671. PubMed ID: 25401736
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies.
Largaespada DA
Leukemia; 2000 Jul; 14(7):1174-84. PubMed ID: 10914539
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
16. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
[TBL] [Abstract][Full Text] [Related]
17. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic drivers dictate immune control of acute myeloid leukemia.
Austin RJ; Straube J; Halder R; Janardhanan Y; Bruedigam C; Witkowski M; Cooper L; Porter A; Braun M; Souza-Fonseca-Guimaraes F; Minnie SA; Cooper E; Jacquelin S; Song A; Bald T; Nakamura K; Hill GR; Aifantis I; Lane SW; Bywater MJ
Nat Commun; 2023 Apr; 14(1):2155. PubMed ID: 37059710
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of the functional integrity of mouse hematopoiesis by EED and promotion of leukemogenesis by EED haploinsufficiency.
Ikeda K; Ueda T; Yamasaki N; Nakata Y; Sera Y; Nagamachi A; Miyama T; Kobayashi H; Takubo K; Kanai A; Oda H; Wolff L; Honda Z; Ichinohe T; Matsubara A; Suda T; Inaba T; Honda H
Sci Rep; 2016 Jul; 6():29454. PubMed ID: 27432459
[TBL] [Abstract][Full Text] [Related]
20. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
